Fourth International Nice/ Springfield Symposium on Advances in Alzheimer Therapy
April 10-14, 1996
Nice, France

Organizers:

Philippe Robert (Nice)
Ezio Giacobini (Springfield)
Robert Becker (Springfield)

Southern Illinois University
School of Medicine – 1218
P.O. Box 19230
Springfield, IL 62794-9230
U.S.A.
Telephone: (217) 785-4414
FAX: (217) 785-4413

Clinique de Psychiatrie
Université de Nice Sophia Antipolis
Hopital Pasteur
30, Av. de la Voie Romaine
06002 Nice, France
Telephone: 33-92-03-79-93
FAX: 33-93-53-32-88

March 28, 1995

Council for Tobacco Research USA Inc.
Attn: George A. Hashim, Ph.D.
Associate Res. Director
900 Third Avenue
New York, NY 10022

217-785-2185
Giacobini

Dear George:

I am aware of the fact that the Council for Tobacco Research has supported a number of meetings in the field of nicotine and neurodegenerative diseases. Our upcoming meeting in Nice is unique as far as concentrated on the effect of nicotine and nicotinic derivatives in the treatment of Alzheimer disease. As you know, there are now nicotinic compounds being tested clinically for their therapeutical property on Alzheimer disease. We are planning, like in the previous meetings, to dedicate an entire session to this subject.

Numerous pharmaceutical companies are competing to develop a drug to treat Alzheimer's disease. Our understanding of the disease, and thereby our ability to pursue new therapeutic pathways, is increasing rapidly. The **Fourth International Nice/Springfield Symposium on Advances in Alzheimer Therapy** will be held April 10-14, 1996 in Nice, France. As documented by the enclosed preliminary program and invited speakers, at this conference there will be an in-depth review of all Alzheimer therapies currently under development or approved, and presentation of the state-of-the-art of promising research. Mechanisms of drug action will be reviewed at the cellular and molecular level. In-depth discussions will follow presentation of results from clinical trials using new drugs. Discussions of new strategies in drug design and clinical trials will be presented. Particular attention will be given to drugs designed to slow deterioration and progression of the disease.

In addition to these therapy and research reviews that have been so well received at our three earlier conferences (1988, 1991, 1994), we have included two days of additional focused update. Distinguished speakers will address fundamental issues in the design of clinical trials, including a session to update attendees on the progress made toward international standardization of AD drug approval regulations. A second new focus is an international perspective on pharmaco-economic assessment, the legal and ethical status of AD research and the relation of national research priorities to drug development.